LOS ANGELES, Nov. 21, 2014 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTCQB:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery method to apply almost any active ingredient to a topical drug. It has recently shown promising results for acne sufferers with the minimal side effects that are usually associated with other medications.
According to the American Academy of Dermatology, acne is a problem that affects approximately 40 to 50 million Americans. While both genders are affected by acne, higher levels of testosterone in men often lead to a higher prevalence of acne sufferers during adolescence and young adulthood. An increase in hormones called androgens, which are in both genders, also correspond with increased acne.
TetraStem differentiates itself from other Tetracycline-based acne products by implementing a unique transdermal delivery method that the Company believes will increase the efficacy of the drug. TetraStem is designed to kill bacteria and heal the skin. ViaDerma believes that patients who apply a drop on the infected parts three times a day will see results within 24-48 hours and resolution within two weeks. TetraStem's active ingredient may help regenerate skin so there is minimal scarring which leaves the patient with very little evidence of previous acne problems.
"It has been tested in Florida, Oklahoma and California," said ViaDerma, Inc. CEO Dr. Christopher Otiko. "The subjects have been pleased with the results. They had tried other medication without success and were impressed with TetraStem's results."
About ViaDerma, Inc.
Founded in 2014 by Dr. Christopher Otiko, ViaDerma, Inc. (VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, TetraStem, uses an innovative transdermal delivery method to apply almost any active ingredient to a topical drug. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. For more information, please visit www.viadermalicensing.com.
Forward Looking Statements
This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements regarding the outlook of the Company's business and results of operations. By nature, these risks and uncertainties could cause actual results to differ materially from those indicated. Generally speaking, any statements using terms such as "will," "expect," "anticipate," or "may," or which otherwise predict or address future results or events, are likely to contain forward-looking statements. It is important to note that actual results may differ materially from what is indicated in any forward-looking statement. Readers should consider any forward-looking statements in light of factors that could cause actual results to vary. These factors are described in our filings with the SEC, and readers should refer to those filings, including Risk Factors described in those filings, in connection with any forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Dr. Christopher Otiko Chief Executive Officer ViaDerma, Inc. firstname.lastname@example.org 818-836-2475Source:ViaDerma Licensing